Passive Immunity: How Monoclonal Antibodies Protect Without Training the Immune System

Passive immunity is borrowed protection. Instead of prompting the body to manufacture its own antibodies, a clinician injects antibodies that were made in advance, and they start neutralizing a pathogen within hours. Monoclonal antibodies such as palivizumab and nirsevimab use this route against respiratory syncytial virus (RSV): they latch onto the virus, block it from entering cells, and shield the recipient on the first day. The catch is that the shield fades as those antibodies are cleared, and it leaves no lasting immune memory. In that sense it is the mirror image of a vaccine.

Key points#

• Passive immunity supplies finished antibodies, so protection is immediate but temporary and builds no memory.
• A vaccine works the opposite way: slower to start, but durable because the recipient's own cells learn the pathogen.
• Palivizumab requires monthly dosing across the RSV season; nirsevimab lasts a whole season from one injection thanks to a half-life extending change.
• A headline like "79 percent effective" is a relative figure; the absolute risk reduction and the number needed to immunize show how much real-world benefit a dose buys.

Borrowed antibodies versus a trained immune system#

The clearest way to understand passive immunity is to contrast it with the vaccine most people already know. A vaccine presents the immune system with an antigen and then waits while the body's own B cells and T cells learn it, produce antibodies, and lay down memory cells. That process takes weeks, but the reward is durability: once memory exists, protection can be regenerated quickly and can last months or years.

Passive immunity skips the school entirely. As a review of passive immunization in the primary literature describes it, preformed antibodies are handed to a susceptible host to give immediate but short-lived protection, with the host's own response never switched on. Nothing is learned, so nothing is remembered. The moment the antibody is in your bloodstream you are protected; the moment it clears, you are not.

This trade of durability for speed is not a flaw to engineer away. It is the whole point. When the dangerous window is narrow and arrives early, waiting weeks for a home-grown response is not an option, and ready-made protection is exactly what is needed.

Why one molecule and one clone matter#

The workhorse of passive immunity is immunoglobulin G (IgG), a Y-shaped serum protein of roughly 150 kilodaltons that circulates and grips a defined target. Its two arms recognize the pathogen; its stem interacts with the rest of the immune system and with the machinery that governs how long the antibody survives.

Antibody products come in two flavors, and the difference is practical. Polyclonal preparations pool antibodies from many B cell clones, each keyed to a slightly different feature of the target. Monoclonal antibodies descend from a single clone, so every molecule binds the same site in the same way. That uniformity is what lets a monoclonal be dosed like a conventional drug, with predictable behavior from one vial to the next. It is also why the RSV products below are aimed at one exact structure on the virus rather than a scattershot of sites.

A useful wrinkle sits at the border between active and passive immunity. When a pregnant person receives an RSV vaccine, that is active immunization for the mother, but the antibodies she generates cross the placenta and protect the newborn passively. The infant, in effect, inherits protection it never built.

Two RSV antibodies, a decade of engineering apart#

Palivizumab was the first antiviral monoclonal antibody to see broad clinical use. It binds antigenic site II on the RSV fusion (F) protein and stops the virus from fusing with and entering host cells. Its limitation is pharmacokinetic. With a half-life of about 18 to 21 days, its level drops too quickly to cover a season, so it must be re-dosed by intramuscular injection every month while RSV circulates. A review of its trial record traces approval to the pivotal IMpact-RSV study, in which palivizumab cut RSV hospitalization by roughly 55 percent in relative terms among high-risk infants.

Nirsevimab is what a later generation of protein engineering produced. A small set of amino-acid changes in the antibody's stem (the YTE modification) tightens its grip on the neonatal Fc receptor, the recycling system that rescues IgG from being broken down. That single tweak stretches the half-life to around 71 days, long enough for one injection to blanket an entire RSV season, and it keeps neutralizing antibody levels roughly ten times higher than monthly palivizumab achieves, as a recent review of RSV monoclonals summarizes. The U.S. Food and Drug Administration approved nirsevimab in July 2023.

The efficacy signal is strong and consistent. Pooled trial data cited by the CDC Advisory Committee on Immunization Practices report 79.0 percent efficacy against medically attended RSV lower respiratory tract infection, 80.6 percent against RSV hospitalization, and 90.0 percent against intensive care admission. On that basis the committee recommended a single dose for all infants younger than eight months who are born during or entering their first RSV season.

Reading past the headline percentage#

Numbers like "55 percent" and "79 percent" are relative risk reductions. They tell you how much the antibody shrinks the chance of an outcome, but nothing about how likely that outcome was in the first place. Two other figures fill that gap, and they are the ones you should ask for.

The absolute risk reduction is simply the difference in event rates between the protected and unprotected groups. Its inverse is the number needed to treat, or in prevention terms the number needed to immunize: how many people must be protected to prevent one event. The palivizumab review gives the raw rates. Among the premature infants studied, RSV hospitalization dropped from 8.1 percent on placebo to 1.8 percent with palivizumab, an absolute reduction of about six percentage points. Dividing one by that difference yields a number needed to immunize near sixteen, meaning roughly sixteen infants had to receive the antibody to keep one out of the hospital.

That number is not a fixed trait of the drug. It swings with baseline risk. The same relative reduction produces a smaller number needed to immunize (more benefit per dose) in a high-risk group and a larger one in a low-risk group. This is why sensible prevention decisions weigh who is being protected: the percentage alone cannot tell you how many doses stand behind each hospitalization avoided. Reading any prevention claim well means tracing the absolute numbers underneath the headline.

The bottom line#

Passive immunity buys speed at the price of durability. Against RSV, a monoclonal antibody gives an infant immediate, well-characterized protection during the exact weeks they are most vulnerable, then washes out, which is why these products are re-dosed each season rather than remembered like a vaccine. Judging their worth means looking past the relative percentage to the absolute risk reduction and the number needed to immunize, because those figures, anchored in the treated group's baseline risk, are what reveal how much protection a dose actually delivers.